Novartis signs gene therapy deal with Voyager for $100 million upfront

(Reuters) – Voyager Therapeutics said on Tuesday Novartis would pay it $100 million upfront in cash as part of a licensing deal to develop gene therapy candidates.

(Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)